Ivana Đurić-Filipović1, Marco Caminati2, Gordana Kostić3, Đorđe Filipović4, Zorica Živković5. 1. Faculty of Medical Science Kragujevac, Department of Immunology, Svetozara Markovica 69, Kragujevac, 34000, Serbia. drivanica@yahoo.com. 2. Unita di Allergologia Centro Regionale di riferimento per la prevenzione, la diagnosi e la terapia delle malattie allergiche Ospedale Universitario Borgo Trento, Piazzale Stefani 1, Verona, Italy. 3. Children's Hospital, Clinical Centre Kragujevac, Zmaj Jovina 30, 34000, Kragujevac, Serbia. 4. Institution for Emergency Medical Care, Bulevar Franša Depera 5, 11000, Belgrade, Serbia. 5. Children's Hospital for Lung Diseases and Tuberculosis, Medical Center "Dr Dragisa Misovic", Heroja Mihajla Tepića 1, 11000, Belgrade, Serbia.
Abstract
BACKGROUND: The incidence of asthma and allergic rhinitis (AR) is significantly increased, especially in younger children. Current treatment for children with asthma and allergic rhinitis include allergen avoidance, standard pharmacotherapy, and immunotherapy. Since standard pharmacotherapy is prescribed for symptoms, immunotherapy at present plays an important role in the treatment of allergic diseases. This article presents insights into the up-to-date understanding of immunotherapy in the treatment of children with allergic rhinitis and asthma. DATA SOURCES: PubMed articles published from 1990 to 2014 were reviewed using the MeSH terms "asthma", "allergic rhinitis", "children", and "immune therapy". Additional articles were identified by hand searching of the references in the initial search. RESULTS: Numerous studies have shown that sublingual application of allergen specific immunotherapy (SLIT) is an adequate, safe and efficient substitution to subcutaneous route of allergens administration (SCIT) in the treatment of IgE-mediated respiratory tract allergies in children. According to the literature, better clinical efficacy is connected with the duration of treatment and mono sensitized patients. CONCLUSIONS: At least 3 years of treatment and stable asthma before the immunotherapy are positive predictors of good clinical efficacy and tolerability of SLIT. SLIT reduces the symptoms of allergic diseases and the use of medicaments, and improves the quality of life of children with the diseases.
BACKGROUND: The incidence of asthma and allergic rhinitis (AR) is significantly increased, especially in younger children. Current treatment for children with asthma and allergic rhinitis include allergen avoidance, standard pharmacotherapy, and immunotherapy. Since standard pharmacotherapy is prescribed for symptoms, immunotherapy at present plays an important role in the treatment of allergic diseases. This article presents insights into the up-to-date understanding of immunotherapy in the treatment of children with allergic rhinitis and asthma. DATA SOURCES: PubMed articles published from 1990 to 2014 were reviewed using the MeSH terms "asthma", "allergic rhinitis", "children", and "immune therapy". Additional articles were identified by hand searching of the references in the initial search. RESULTS: Numerous studies have shown that sublingual application of allergen specific immunotherapy (SLIT) is an adequate, safe and efficient substitution to subcutaneous route of allergens administration (SCIT) in the treatment of IgE-mediated respiratory tract allergies in children. According to the literature, better clinical efficacy is connected with the duration of treatment and mono sensitized patients. CONCLUSIONS: At least 3 years of treatment and stable asthma before the immunotherapy are positive predictors of good clinical efficacy and tolerability of SLIT. SLIT reduces the symptoms of allergic diseases and the use of medicaments, and improves the quality of life of children with the diseases.
Authors: Michael Blaiss; Jennifer Maloney; Hendrik Nolte; Sandra Gawchik; Ruji Yao; David P Skoner Journal: J Allergy Clin Immunol Date: 2011-01 Impact factor: 10.793
Authors: Ronald Dahl; Alexander Kapp; Giselda Colombo; Jan G R de Monchy; Sabina Rak; Waltraud Emminger; Bente Riis; Pernille M Grønager; Stephen R Durham Journal: J Allergy Clin Immunol Date: 2007-12-26 Impact factor: 10.793
Authors: Albrecht Bufe; Peter Eberle; Eivy Franke-Beckmann; Jürgen Funck; Martin Kimmig; Ludger Klimek; Roland Knecht; Volker Stephan; Bente Tholstrup; Christian Weisshaar; Friedrich Kaiser Journal: J Allergy Clin Immunol Date: 2009-01 Impact factor: 10.793
Authors: Anthony J Frew; Richard J Powell; Christopher J Corrigan; Stephen R Durham Journal: J Allergy Clin Immunol Date: 2006-02 Impact factor: 10.793
Authors: Maria Angela Tosca; Amelia Licari; Roberta Olcese; Riccardo Castagnoli; Alessia Marseglia; Gian Luigi Marseglia; Michele Miraglia Del Giudice; Alberto Martelli; Mauro Calvani; Carlo Caffarelli; Marzia Duse; Claudio Cravidi; Fabio Cardinale; Giorgio Ciprandi Journal: Acta Biomed Date: 2020-09-15